Q1 25/26

Jul 22, 2025

Summary

Q1 revenue rose 118% YoY, while gross margin fell to 48.5% amid inventory drawdown and product mix; management cited ~53% as the normalized level for the current portfolio. Capacity expansion, new launches and a growing CDMO pipeline underpin FY26 confidence.

Ladies and gentlemen, good day and welcome to the Q1 FY 2026 earnings conference call of Blue Jet Healthcare. As a reminder, all participant lines will be in the listen only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. I now hand the conference over to Mr. Advait Bhadekar. Thank you, and over to you, sir. Thank you, Viren. Good evening and a warm welcome, everyone, to Q1 FY 2026 earnings call of Blue Jet Healthcare Limited. Please note the investor presentation and the financial results are available on the company website and the profit streams. Also, anything said on this call, which reflects our outlook for the future or which could be construed as a forward-looking statement, must be reviewed in conjunction with the risks that the company faces. The conference call is being recorded and the transcript along with the audio of the same will be made available on the website of the company as well as on the exchange. Please also note that the audio of the conference call is a copyright material of Blue Jet Healthcare Limited and cannot be copied, rebroadcasted, or attributed in press or media without specific and written consent of the company. From the management we have with us Mr. Shiven Arora, Managing Director, Mr. V.K. Singh, Chief Operating Officer, Mr. Ganesh Karuppannan, Chief Financial Officer, and Mr. Sanjay Sinha, Deputy Chief Financial Officer. Now I would request Mr. Shiven Arora, Managing Director of Blue Jet Healthcare Limited, to provide you with the updates for the quarter ended 30th June 2025. Thank you, and over to you, sir. Thank you, Advait. Good evening, everyone. Thank you for joining us today. I am pleased to share that we started FY 2026 on a solid note. Our Q1 results reflect sustained momentum from the second half of last year, despite the expected normalization of some operating parameters. Importantly, this quarter reaffirms the resilience of our business model and the strength of our customer relationships. Financial performance overview. Revenue from operations of Q1 stood at INR 3,548 million, up 4% sequentially and 118% year-on-year, driven by consistent volume growth across our PI, API and contrast media platforms. EBITDA came in at INR 1,210 million, translating to a margin of 34%. Lower quarter-on-quarter due to phasing of production, inventory normalization, and product mix. PAT for the quarter was INR 912 million with a net margin of 25.7%. On a year-on-year basis, EBITDA and PAT grew by 178% and 1.4% respectively, on a strong base volume expansion and enhanced operational scale. We continue to generate healthy operating cash flows with disciplined capital deployment across R&D and capacity expansion. Business segment commentary. Pharma intermediates and API. This segment maintains robust momentum with the cardiovascular intermediate continuing to scale under long-term contracts. We are seeing strong customer demand visibility and expect additional launches in H2. In contrast, media commercial volumes from new molecules launched in Q4 FY 2025 have now stabilized. We expect sequential growth in H2 as client uptake ramps up. High-intensity sweeteners. Volumes remain steady. ASPs are stabilizing after a soft FY 2025. Our value-added variant strategy remains intact. In terms of operational and strategic highlights, we completed phase II expansion in unit 2, which is now fully operational. Progress continues at Unit 3 Mahad, where the construction is on schedule for H2 FY 2026 commissioning. This plant is being designed for continuous processing. In terms of the R&D center, INR 400 million committed towards capabilities in amino acid derivatives and late-stage intermediates is under motion. Our employee cost and utility overheads remain well controlled, with cost of goods sold optimizing. In terms of outlook, we remain confident in our outlook for FY 2026. Demand visibility across key customers is healthy. Capacity is now in place and product pipelines are expanding. In particular, we see structural tailwinds from de-risking of supply chains by global innovators, increasing adoption of complex APIs and NCE intermediates, growing traction in contrast media, especially with new molecules under validation. We expect the business to maintain strong growth and margin trajectory through FY 2026, and we remain focused on disciplined execution, innovation-led partnerships and long-term value creation. With that, I will now invite our CEO, Mr. V.K. Singh, to walk you through the operational update. Thank you. Hi. Good evening, everyone. I will start by a few notes on the capacity. The new CDMO capacity catering to the PI and CMI segment at Unit 2 Ambernath is now fully on stream. The advanced intermediate to the contrast media and NCE that we had indicated will be launched from this capacity is now commercial. Revenues from this molecule can be cited in the quarter that is gone by. This new block now has a consistent production schedule due to high order visibility. The cardiovascular intermediate that we to the innovator has seen a huge uptick as compared to Q1 FY 2025, and has shown consistent growth over the last several quarters as the end molecule is doing well in U.S., Europe, and ROW markets. Currently, we are at 60% capacity utilization, and we believe we have the capability to capture any further uptick in demand should that happen in the near future. At Unit III Mahad, we were creating a capacity for backward integration for the CMI segment. This is a highly engineered plant based on flow synthesis, will be the first that we will have for making the KSM for our CMI product. Work is in progress in full swing and as indicated, the site should be ready for validations and will go on stream in second half of FY 2026. With this plant going on stream, we will strengthen our position as a credible and leading supplier of CMI to all the leading innovator companies in this segment. We further demonstrate a resolve to retain a leadership position in the CMI segment. With this backward integration, we not only achieve strategic independence, but also insulate the business from significant volatility of the key raw material pricing. As a country, we are experiencing significant tailwinds for the CDMO business. There has been a huge surge in RFPs. While our focus has historically been on the chronic segment, we had been building capacity to supply building blocks and peptide fragments to innovators, and also the global CDMOs engaged in this field. Given the interest that we are seeing in this segment, we are advancing with a plan to build a multipurpose plant at Mahad and a state-of-the-art R&D center at Hyderabad. The GMP compliant, approximately 30-reactor plant will be a versatile plant with capability to supply from a few kilos to multi-tons to our CDMO clients in any geography. At Mahad, both in the block meant for vertical integration and the multipurpose block, we believe, which will go on stream in H2 FY 2027. A high level of automation is being built to ensure batch-to-batch consistency, optimal yields, and risk-proof operations. As a consequence of this high level of versatility and automation that has been built into the Unit III Mahad, we envisage that the earlier planned CapEx of INR 250 crore for Unit III shall increase to about INR 300 crore. Of this, about INR 100 crore has already been incurred, and the balance INR 200 crore will be incurred up to FY 2027. The state-of-the-art R&D center being built at a cost of about INR 40 crore shall focus on the newer chemistry platforms like peptides, intermediates for GLP-1s, biocatalysis, with a focus on immobilized catalyst and work to augment and strengthen the innovator-oriented pipeline of the company with a focus on chronic diseases. Today at R&D, we are tracking about 20 new opportunities with high client interest and visibility. About 30% of these, which is approximately six, are in late phase III or commercial phase. As a company, we are committed to carbon sequestration. We are conscious about the environment and our carbon footprint is consistently reducing. We contribute about 70% of our overall energy consumption from wind and solar. Now I come to the most interesting part of this readout, our future expansion plans. In the last four years, we have quadrupled our manufacturing capacity. In the next two to three years, maintaining the same growth momentum, we plan to add another 1,000 KL capacity to keep in step with our aspiration, to keep in step with our medium-term goals, and to keep in step with the business commitments which have been backed by clients lock-ins. To achieve this, we plan to acquire a large land parcel where we will lay the foundation of a globally competitive and world-class CDMO. This land will be developed in three phases. In phase one, we plan four blocks, two dedicated to contrast media, one for high-intensity sweetener, where we plan to manufacture another sweetener from a successive generation to what we already have for some of our existing clients, and the fourth will be a multipurpose block. With this, I hand it over to Ganesh to take you through the financials. Thank you, VG. Good evening, everyone. I will walk you through our key financial and operational highlights for Q1 FY 2026. While Shiven talked about the quarterly performance, I repeat, we sustained top-line momentum in Q1 with broad-based contribution across all three product categories. Revenue from operations stood at INR 3.54 billion, up 4.5% sequentially and 118% year-over-year. EBITDA for the quarter was at INR 1.2 billion or 34.1% of the sale, which is 7% sequentially declining, yet a 173% increase over Q1 last year. Profit after tax stood at INR 912 million, with a PAT margin of 25.7%, down from Q4, but up by 148% year-over-year. On a full year basis, Q1 FY 2026 compared favorably with Q1 FY 2025 across revenue, EBITDA, and PAT, reflecting sustained operating leverage and commercial traction. We will explain the variance more of sequential quarter with current quarter, which could be more relevant. I just move on to the gross margin. The gross margin for the quarter was 48.5%, down by 6.5% from 55% in Q4. I will explain the movement. If you notice in the P&L, there is a reduction in the finished goods and WIP to the tune of INR 750 million in Q1, as against an increase of INR 100 million in Q4 2025. This means a INR 750 million drawdown in finished goods and WIP inventory versus INR 110 million built up in Q4. As overheads are absorbed in inventory valuation, this decline in inventory releases more overheads into the P&L, compressing the margin. Of the 6.5% reduction in gross margin, roughly more than 4.4% is attributable to this inventory adjustment and 2.1% to the product mix, specifically on account of higher contribution by PI/API segments and lower contribution by others segment. If you were to take a cumulative number of Q4 and Q1, you would end up with a 53% gross margin, which explains this 4.5% decline is merely on account of release of inventory in this quarter. There were no major changes in key raw material prices, and our procurement cost remains well managed. Moving on to certain other P&L considerations, a INR 27 million GST demand impacted EBITDA by approximately 0.7% during the quarter, which is a one-time effect. Similarly, Forex gain were lower due to US dollar depreciation in Q1 leading to a muted Forex gain in Q1. Moving on to segmented performance, PI and API grew by 8.2% quarter-on-quarter, and we were able to sustain the momentum. Artificial sweetener grew 17.4% quarter-over-quarter, reflecting a recovery from muted historical performance. Contrast media saw a 3.9% quarter-over-quarter dip, mainly due to phasing. However, the outlook is positive with commercialization of new iodinated intermediate and supplies of gadolinium-based products, which are planned in this quarter. From a balance sheet perspective, we hold INR 2.7 billion in cash and treasury instrument, and we continue to generate positive operating cash flows aligned with internal expectations. In terms of CapEx, during Q1, we approximately incurred an expenditure of INR 280 million. Our guidance for FY 2025 remained unchanged. We remain confident of achieving our FY 2026 goals through consistent cost discipline, capacity utilization, and pipeline progression. With this, I hand over back for the Q&A session. Moderator, you can line up the question and answer. Hello? Hello. They are not able to listen. At where they would respond, right? Even at least the moderator will respond. Volume to come near. Hello. Please be patient. There are some technical glitches we are solving for. Please be patient for a minute. There is some technical glitch with the moderator. Please hold on for few minutes. Hello. Advait sir. Hello. Yeah. Am I audible now? Yeah. Yeah. Sorry for the inconvenience, sir. You can line up the questions now. Yes, sir. Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on their touch-tone telephone. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. We have our first question from the line of Kunal Dhamesha from Macquarie. Please go ahead. Can you hear me? Yeah, we are able to hear you. Good evening, and thank you for the opportunity, and congratulations on great top-line momentum. I have question on gross margin. I think the clarification was good, but let's say from here on, how should we think about the run rate, maybe on an annual basis? What's the range that we should look at? Is it 53% kind of run rate that we should look at adjusting for this 4.5% one-off? Secondly, let's say once the iodinated ABA-HCL kind of grows, how that 53% could move. Any clarity on that would be helpful. I have more questions. I will come back. Yeah. See, if I look at this change in the finished goods we are actually back to the 53 levels. This is just an issue which is relevant only for this. On a regular basis, we don't see any change in the gross margin with this current product mix. We have couple of new launches which are slated for Q2, Q3, and could actually back or queue. If there is any changes when this iodinated new product comes in, you can actually see the change in the numbers. Should we expect it to improve from the levels, current levels, or how should we think about it? We don't give guidance on the future. Based on the current portfolio mix, it's going to be 53. We will be in a position to sustain similar levels in the coming quarters. Okay. This 53 you've mentioned, is the 53 days of finished good inventory? No, this is 53% of gross margin. 53% of gross margin. But let's say finished good inventory now, where would we and then is it in line with our expectations? In terms of inventory days, there is no significant change. Okay. It came down by 131 days. That is working capital to total turnover. We should be around similar range way forward. Okay. Sure. Manoj, second one on the iodinated intermediate. We are saying that the block is ready, capacity is ready, and it would get commissioned or will start supplying in Q2. Is this the way to understand? Yes. That is the right assumption. Sure. What is the capacity in terms of, let us say, reactor capacity or let us say tons, if you could share? How do we expect the ramp-up to be? Will it be a gradual ramp-up or step ramp? In terms of what I can share right now, the net realization per kg improved significantly with this launch. I will not be able to give the volume or share the revenue. From a criticality standpoint and our growth journey, this is a fairly good needle mover. Mm-hmm. Sure. One on the pharmaceutical intermediate. I believe that we had suggested that 120 KL capacity is what we had put for the cardiovascular intermediate. Is that number correct? I just wanted to ask if the moderator is online. Yes, sir. All right. Okay. Yeah, that's the right assumption. 120 KL is what we've indicated. That's the right number. Happy to go on the next question, please. Thank you. Yeah. I have more question, I'll join back the queue. Yeah. Thank you. Thank you for the response. Thank you. Ladies and gentlemen, in order to ensure that management is able to address questions from all the participants in the conference, please limit your questions to one or two questions per participant. Do you have any follow-up question? We request you to rejoin the queue. The next question is from the line of Meet Katrodia from Nivesha. Please go ahead. Yes, sir, thank you so much for the opportunity. Sir, I want to understand a little deeper in terms of gross margin. Like gross margin fell 6.5% this quarter and 4.4% impact due to changes in inventory. Means we sold much of the higher cost inventory we have in last quarter, right? Could you break down how much of the gross margin drop came from under absorbed fixed overhead or pricing change, or is it like one-off inventory adjustment? Basically, I want the breakup of 4.4%. See, whenever you have a change in finished goods Yes, sir. Whatever overhead which gets inventorized gets released to the P&L. For example, if you draw from your finished goods, whatever overheads that has been inventorized gets released to the P&L. So there is no breakup for 4.4. It is totally the overheads. Totally overheads. Yeah. What got inventorized in the last quarter, because this time our closing finished goods is much lower compared to the previous quarter. Okay. Technically means we have actually sold the finished goods of last quarter in this quarter, and any associated overheads relating to those stock get released to the P&L. That's the way you have to look at it. Okay. The figure, 4.4% changes in inventory contains all the overheads, right? There is nothing raw material cost or maybe- No. My understanding is right? You are right. Yeah. Meet, I'll just add here. Yes, sir. Whenever inventory gets reduced, your COGS goes up in accounting language. Okay. Yeah. Exactly has happened. If you see the last four column of the P&L, each year, COGS has reduced. Mm-hmm. Yes. Because of this change in inventory, the COGS has gone up. The simple language, when inventory goes down, your COGS goes up, and it affects your loss contribution. I think- Okay, understood. Thank you, sir. Yes. Okay. Yeah. Next one is, sir, like on pharma intermediate side, what kind of visibility do we have from innovator, like as the product expand into new geographies and settlement with generic ANDA filer is giving good long-term visibility. Are you seeing increased demand? Will it lead our PI segment to grow from this quarterly run rate of INR 200 crore or do we anticipate growth to taper off due to rising competition? Once again, we would reiterate that we do not really give a guidance like this. But then you should not assume a quarterly run rate, right? Yes, sir. Perhaps you have to look at a larger time segment. In the CDMO business, quarter is not a very good indication. That's number one. Yes, sir. Number two, as far as the end molecule is concerned, the growth numbers are very encouraging. Yes, sir. There is a very interesting life cycle management also happening at Esperion, where they are coming out with newer products. Yes in combination with this bempedoic acid. I guess overall, the tidings of the market are excellent for the molecule. We don't see any issue at all. We are poised for good growth. Got it, sir. Sir, in contrast media, PDI is iodixanol low. I'm sorry to interrupt. May I request you to rejoin the queue as there are several participants waiting in the queue. Yes, sir. Thank you so much. Thank you. The next question is from the line of Piyush Kumar from Magnus. Please go ahead. Yeah. Am I audible? Yeah. Sir, my question is regarding the entire three segments of your business. Which is the most bullish segment that you are on? Which segment is getting the most calls from clients and the entire industry? What do you think about that, sir? For us, contrast media is our flagship vertical and the mainstay of the business. We are very predominantly contrast media-focused company. On the other side, the PI business you have seen has gained great traction. There, the addressable market is much larger. Much, much larger. Much bigger than contrast media. Because of the China plus one tailwinds or whatever you say, there's a lot of RFPs that we are getting over there. We have been so well-positioned in the sweetener business, and we are with almost all clients at the FMCG. The new generation or the next generation sweetener or the new sweetener that we will add will give a fillip to whatever turnover we are doing with sweetener business. Overall, I would say that today, all three product verticals are poised for a healthy growth. Okay, sir. Sir, my last question is, how should one look at your business? Should we look at the QOQ or just Y-over-Y, sir? That's my question, sir. See, if you look at our performance for the last several quarters, you would see that we have been very consistent quarter on quarter. But then for any B2B business, particularly a CDMO business, a quarter may not be a very good indication. Right? There are businesses where if you will slice and dice, you will see a lot of consistency in daily sales. But this is not that type of business. That's all that I would say at this point of time. Okay, sir. Thank you, sir. All the best. Thank you. Thank you. The next question is from the line of Shashank Krishnakumar from Emkay Global. Please go ahead. Hi. Thanks for taking my question. I think we did attribute to phasing of production this quarter. Just wanted to check if production levels in 1Q are meaningfully lower, because it is also in connection with the gross margins. Given that we have very strong order book visibility. Just wanted to understand that. Maybe it is the wrong wording I had used. It is not phasing out of inventory. It is basically reduction in inventory. I think that is the way you ought to look at it. Production or utilization levels were not lower on a quarter-over-quarter basis, right? Just wanted to understand that. No, the productions are based on customer orders, so we have a very sustained production. This is something, certain inventory produced in the last quarter got sold in this quarter. Got it. Thank you. That is helpful. My second question was on the new launches that you pointed to in 2Q and 3Q. Does that include the iodinated intermediate and any other launch from other business segments? Just want to understand which were the two new products that you were alluding to. In contrast media itself from an H2 perspective, there is this iodinated ABA-HCL that we spoke about, and there is the backward integration that we are doing. These are the two material launches. However, there are few other intermediates that we supply to newer contrast agents. These are newer applications with some innovators. These are all lab quantities, but have a promising future. This is more about contrast media. About pharma intermediates? Pharma intermediates also, there are new opportunities that we are tracking. As I mentioned, some of them are in phase III and late phase, and a couple of them are already commercial. I think there are interesting opportunities there also. Got it, sir. Thank you. Thank you, and all the best. Thank you. The next question is from the line of Arpit Tapadia from IG Family Office. Please go ahead. Hello. Am I audible? Yes, Mr. Tapadia. My first question is regarding the land that we have returned to the authorities and got our refund back. Any particular reason in behind? Actually, our application had been for a much, much larger parcel. But today, in the red category, Gujarat does not have too much land. So we got about 8 acres. We took that, but then we felt that was subscale because now we have spotted and in the process of finalizing a much, much larger piece of land. Therefore, it was logical for us to surrender this in view of the much larger parcel of land. That we would be acquiring very shortly, and we will make an announcement about that, which is in step with the aspiration that the company has. Got it. My second question is in line with the previous participant only. Since we have lowered down our inventory into this quarter, and our sales at overall level is more than the previous quarter, then we must have ramped down our production level into this quarter. Yeah. Our closing inventory of finished goods is lower compared to previous quarter. And we have the production plan in place for Q2 and Q3, which will actually get back to the original levels. Got it. So what is our sustainable level of inventory that we want to maintain? No, it is more than sustainable level. It is more to do with the customer order and because we make based on customer order, so it is dependent on that. Okay. I will fall back into the queue, sir, for the question. Thank you. The next question is from the line of Aman Soni from Invest Analytics Advisory LLP. Please go ahead. Hello, Mr. Aman? My question is already answered. The next question is from the line of Mr. Ayush Agarwal from MAPL Value Investment Fund. Please go ahead. Hi, sir. I hope I am audible. Yeah. Okay, great. Ganesh, sir, this is a question for you on the inventory. I am sorry for harping on it again. But I do not believe that we record finished goods on the selling price. We record finished goods on the lower of cost, basically. I am reading your annual report note, which has accounting policy on finished goods, and it is clearly mentioned that we value at lower of cost and NRV. So, the overheads that we are talking, which have been brought from last quarter to this quarter, does not really make a lot of sense to me. Even if I look at our past quarters' cost of raw material, they have never actually crossed 46%, 47%. While I understand that pharma intermediate has scaled up in the last three, four quarters, when it scaled up in December 2024, then also our cost of raw material was just 45%, which was the same in March 2025 number as well. If you can really help us understand what happened to our gross margin this quarter, it would be helpful. Finished goods is never valued on sale price. Okay? It is basically raw material plus associated overheads. Any direct overheads gets allocated. This is the accounting principle every company follows in valuing the finished goods. Okay? You can easily understand what is the raw material cost and what is the direct overheads which gets allocated. In a quarter where you have a larger finished goods, you would have actually inventorized certain overheads, the direct overheads. If you maintain similar inventory levels quarter-on-quarter, you don't see that impact in the P&L. In our case, between Q4 and Q1, the finished goods inventory came down in Q1 to the tune of INR 75 crore, which is basically the raw material cost plus direct overheads allocated. Okay? If you just see what is the overheads which got allocated, the difference in overheads between Q4 and Q1 of this current quarter, the impact is close to 4.4%. That comes to around INR 17 crore-INR 18 crore. Do you mean that we did not recognize that cost last quarter and our numbers were higher by that last quarter? Yeah. If you want to understand more clearly, if you just take the Q4 and Q1 of this, the calendar six months, you would get a gross margin of 53%. Understood. Second question, sir, is on the CapEx, which our COO, sir, mentioned that we want to add 1,000 KL capacity in the next 2 to 3 years, and we will start with phase 1 of 4 blocks, 2 of them for CMI, 1 for high-use entities, sweetener and 1 an MPP block. Given the growth happening in the pharma intermediate molecule, and given what our customer is preparing for in the future, why no CapEx towards this as well? I understand we are at 60%, but why no CapEx towards pharma intermediates in the next phase of expansion? I think maybe the voice drained off and maybe you were not able to hear. Pharma intermediates is becoming an important part in the entire scheme of the company. There is 1 block that will come up in Mahad, which we very clearly mentioned. That is like a multipurpose block. We will be catering to this segment. Even for our new big land parcel that we spoke about our expansion plan for the future, there also we mentioned that there is going to be a multipurpose block which would be catering to this third product vertical. I think we are building up good capacity in anticipation of the RFPs that we have. I think just to add on to that, as a company DNA, when we have a customer lock-in and a contract visibility, that is when we initiate a thought process of adding a particular block. That is how we see in contrast media also, we believe that 2 additional blocks should be added due to certain discussions with the customers and the innovators. Just to follow up on this. Given that we are already doing backward integration into KSM for our contrast media intermediate, and we are putting up two more blocks for contrast media, what could be the roadmap for contrast media from here? The end formulation market is definitely growing, and from $6.7 billion in terms of end formulation is projected to become $10 billion in the next few years. So in anticipation of this growth, we have a strong push from our customers also to add capacities to take care of these growing demands. Are we going to API? Mr. Ayush, I am sorry to interrupt. May I request you to rejoin the queue? The next question is from the line of Bansi Desai. Please go ahead. Yeah. Hi, thanks for taking my question. My question is again on contrast media. If I just look at this business for us for the last two to three years, we have been in that range or in fact, looking at this quarter's number at INR 97 crores, we are much below our quarterly run rate that we have seen in this business even two years back. So from a INR 500 crore business in fiscal 2023, we came down to INR 480 crores in fiscal 2024. We came down to INR 400 crores in fiscal 2025, probably because of customers, changes in the facility, et cetera. But starting this year, we are again at INR 97 crores. If you can just help us understand, probably two years back, we would have thought that end market is growing at mid to high single digit, Blue Jet Healthcare launching more molecules. You should have grown probably at mid-single digit or higher than that. From there to here, we are still probably at this run rate of INR 97 crores. Are we going to see a step-up again in this business from the new launches that you are guiding? If one has to look at two to three-year view, maybe quarterly is not the right way to look at the numbers, I understand that. But if I have to take a two to three-year view, how should one think about growth for contrast media? Bansi, there are three levers. One is the largest customer, the forecast, whatever they have indicated to us, the iodinated product, and the intermediate for the gadolinium molecule. If we look at all the three together, there is a good probability we should actually get back to the 2023 levels. I think that is our aspiration. So that is what we are working on. This would actually become a new base for us. If we could actually reach the 2023 level in 2025 or 2026, then we can actually build on. You will obviously have the growth on the iodinated molecules. You will actually see the full year impact in FY 2027. The NCE molecule also would grow in 2027, 2028. In the meantime, we do expect certain new opportunities which we are actually planning from FY 2028, 2029, what VK and Shiven alluded to in terms of additional capacities for contrast media. How is the capacity utilization for contrast media? Particularly, you mentioned 60% at an overall level. Is it any different for contrast media? What I mentioned was for the API segment, that particular block that we had created. Okay. Just to give a sense that should there be an increase in demand, we are well poised to capture that. Okay. Overall, I think at a company level, maybe 75%. Okay. Second question, just on API. I am sorry to interrupt. Yes, Bansi. I would request you to please rejoin the queue. The next question is from the line of Ravi Purohit from Securities Investment Management Private Limited. Please go ahead. Yeah. Hi, thanks for taking my question. Sir, I have been reading our environment clearance report for the new Mahad unit. In that, we have provided a list of products where we are adding capacities, and one of them is also API for bempedoic acid. I think so far we have been doing only the intermediate. In bempedoic acid, are we looking to add API capacity as well? Similarly, in contrast media, we are putting up two new blocks in the new large capacity that we are planning to set up over the next two to three years. There also historically, are we looking to add larger API capacities in many of these where the value of the end product, of course, could be significantly larger than what we have been getting in the intermediate. If you could just share some thoughts and some color on where we are headed on either of these, both API as well as the contrast media on the journey from intermediate to whether we will or will not be doing APIs. If you would see our performance over the last couple of years, three, four, five years, you will see that our per KL realizations have gone up significantly and very consecutively, and our per kg realizations have also gone up. From building blocks to intermediates, advanced intermediates. Now, both in our contrast media and API, what we supply to our clients are very advanced intermediates, which are just one or two steps short of the final API. The final API could be a logical extension. As you know, Shiven also mentioned what the DNA of the company is, we always do it with a specific client lock-in and client interest. It has to come from one of our existing clients. We don't wish to participate in the generic space. As far as your reading of our environment clearance is concerned, while the advanced intermediate that we make for bempedoic acid is just two steps away from the final API, many a times we give a laundry list of products because going back to the EC for amendments of the product list is not very convenient nor efficient. Okay. Got it. Thanks a lot, sir. Most of my other questions have been answered. I can back to you in the queue. Thank you. The next question is from the line of Jaikot Prakashkumar from Korman Capital. Please go ahead. My question is answered. Thank you. Thank you. The next question is from the line of Ajay from Niveshaay. Please go ahead. Thank you for the opportunity. My question is on contrast media. As mentioned by the previous participants, the speed or growth has been slow, but we also believe the big scale can be achieved in this business with forward integration. Sequentially, what are your expectations with this segment going ahead? Do we plan to forward integrate? There is a clear roadmap for that. As we mentioned that we always do it for the customers on a CDMO model. We do not participate in the generic space. I think, as it pans out, we will keep you updated. At this point of time, we cannot comment any more than what we have. Got it. Last question, again, this is on the inventory. You mentioned that there was under-absorbed overhead, and this is typically due to the lower production, which we also expect going forward to pick up, which will eventually result in sales in the coming quarter, which will result in better absorption of Pixus. My question is, if in case this doesn't happen, what are the steps being taken to absorb or manage these overheads going forward? If you can also highlight the range of gross margins, what we should look at, that would be helpful. It is not under-absorption of overheads. It is the overheads inventorized in the previous quarter getting released to P&L in this quarter. Okay? It is not that. Under-absorption is completely a different topic. This has nothing to do with under-absorption. But in the press release, it has been mentioned the same. Okay. I'll just check on that. Okay. Because this may be like for you to simplify, if you just take the P&L of Q4 2025 and Q1 2026 P&L and merge it, you can actually understand the net impact, and you would actually see our gross margin is impacted 53%. If I even back calculate, the number comes down to 51.6%. I am not able to clearly understand. In the press release also, it has been mentioned clearly that it is driven by shift in product mix, reduced inventory levels, and resulting in lower overhead absorption. Okay. We will take it offline. I will actually explain the complete calculation on this. Also, sir, last question. Sir, we have plans of fundraise. If you can give details on what are the plans going forward for the same. This is still in the drawing room stage. We are yet to finalize anything. As and when we conclude on this, we will actually communicate. Right now, we have just taken a shareholder resolution, and we are still evaluating the options. Okay, sir. Thank you. Thank you. The next question is from the line of Bansi Desai from J.P. Morgan. Please go ahead. Hi. Thanks again for the opportunity. Just on the API for the cardiovascular product, it appears that the realizations have remained pretty stable. Is that true? Yeah. Therefore, if the realizations, say for instance, were to remain stable, and if we were to see increased uptake in quantity, should we assume this kind of run rate to continue? With the current cost structure, our margins are intact. No, sir, I was talking about the revenue for the C-IAPIs. Yeah. As you know, Bansi, the molecule is doing extremely well, and I think what we have done at an annual level, that we should be able to maintain with some growth in that. Okay, perfect. Thank you so much. Thank you. The next question is from the line of Abhishek Sharma from DNH Satluj Electrodes Private Limited. Please go ahead. Hello. Good evening, sir. Sir, is there any cyclical pattern in the company's revenue organization, just like that in the first half of the financial year typically contributes a lower portion of annual revenues compared to the second half? We don't have any seasonality in our industry. It's all more to do with the customer orders. Sanjay, you want to add on? Basically, this is all related to MTO orders. Made-to-order. As and when order is there, we manufacture. There is no cyclical. It's not a formulation company. Okay. Thank you. Thank you. Thank you. Thank you. The next question is from the line of Vidit Shah from Spark Capital. Please go ahead. Hi. Thanks for taking my question. Sir, two questions I had. Sir, one was, while I understand that inventory has hit the P&L, I would assume that revenue too would be booked in the same quarter. I am still confused around why margins have taken such a sharp decline, unless there were one-off overheads which have been recognized in the quarter. I am happy to take that offline if you may. My second question was on why are we seeing reduced levels of inventory? Why are we consciously reducing levels of inventory in Q1? Basically, in simple words, it says the movement of COGS that has not gone to those. If you see, whenever the inventory goes down, the COGS goes up. I mean, it is simple accounts. That is the impact. So inventory has But the revenue would also go up in the same way, right? So margins may not be impacted. Yes, but the revenue has also gone up. But the stock was lying in the last quarter. It got dispatched this quarter. Okay. If you see the movement, it is the impact of COGS. Of course, overhead and all is there, but it is movement of COGS, basically. Okay. Compare sales minus raw material cost, which is the gross margin, and remove the COGS, still the margin is around 52%. Okay. Maybe we can take that offline. If you could just help me understand why are levels of inventory decreasing. Is that a conscious effort or is this a planned maintenance sort of- No. This is more with customers' dispatch schedule. Each customer has their dispatch schedule. It is more to do with their logistics planning. Okay. Would that be fair to assume then that Q2, the dispatches may not be as much as Q1? Is that how to look at it? Not exactly. This is because we have our production schedule for Q2, Q3. Okay. Whatever happened in Q1 should not have impact on the production of Q2. Okay. Understood. Those were my two questions. Thanks for answering them, and all the best. Thank you. Thank you. The next question is from the line of Kunal Dhamesha from Macquarie. Please go ahead. Hi. Thank you for the follow-up question. My question is primarily on the peptide segment. If you could help us understand the capabilities that we have, what are our aspirations there, and what is the capacity that we are planning, and where it would be, CapEx required? That would be great. See, on the peptide segment, we are working on peptide fragments. At the R&D stage, we are working on some peptides. What is more advanced and what we are discussing with certain innovator companies are the intermediates to the end peptides, some of them being the GLP-1 products, where we are in conversation with certain innovator companies for the intermediate. Basically, we are working on the amino acid derivatives and peptide fragments. Till the time we build our multipurpose plant in Mahad, the smaller requirements that will be there in this segment will be catered to from the multipurpose plant in unit 2. When the Mahad capacity comes in, that will address this business segment and demand. And as I mentioned that in the larger scale of things, when we have this much, much larger land parcel and capacity that we plan to create in the next couple of years, there will be capacity for this segment there also. It will all be in step with the client lock-in and visibility of business that we have. So when we say these fragments, would it be more like dipeptide, tripeptide, or octamer, decamer? What are we trying to achieve here? Then, in terms of the technology that we would be adopting, whether it is chemical synthesis and on a large scale basis, would it continue or we are also looking at the other type of technology available there? See, as I mentioned, that we are doing amino acid derivatives. We will not be making the amino acids which are on fermentation-based technologies. As we speak, we have developed already about 45 peptide fragments. We are not in the library or catalog type of business, say we do 300 or 400. There is a big opportunity over there, but that is not what we are focusing. We are working on those where there is high conviction and client visibility. Since I mentioned peptide fragments, and we are not really talking about the tripeptides or tetrapeptides or the decapeptides. In the new R&D center that we are creating, we will have one lab which will be doing peptide synthesis. But then the high conviction opportunities that we are tracking are more on the fragment side. Sure. Maybe I will take it offline. I need to kind of build this more details around it. Sure. Thank you for your answer. Thank you. Thank you. The next question is from the line of Ravi Purohit from Securities Investment Management Private Limited. Please go ahead. Yeah. My question also was similar to the previous participant's questions too. Amino acid chains and the fragments are not very easy to establish. Is it something that we are working on and will eventually showcase to clients, or we have already established certain processes and certain products on existing showcase to clients? Where are we in that sense? Is it something that we aspire to do or certain products or certain chains we've already established and it's only a matter of talking to the client, showing to them what we are capable of and have a capacity to basically manufacture? Because what we understand is the chain is not very easy to have, produce, and replicate. You need a specialized skill set for this. Yeah. Which we have. We have been working on this type of chemistry for the last 2 and a half years. We have a couple of scientists who are extremely good in this type of synthesis. As I mentioned that we are not in the catalog business. As we speak, we are not venturing now. We already have about 45 products or 45 peptide fragments which are already ready. They can be commercialized almost immediately. And this preparation or this readiness that we have is based upon customer interest. So there is no blue sky gazing in this. Okay. Thank you so much, and all the best. Thank you. Thank you. The next question is from the line of Ankit Sahay from Fusion Capital. Please go ahead. Yeah, hi. My question is on the gross margin. Rather than taking it offline, it would be helpful as most of the participants have this question, so you can bit more clarify on this here itself. What is your question on gross margin? Yeah. You mentioned the right to look it at a consolidated of Q4 FY 2025 and Q1 FY 2026. Why to do that, and why the revenue should be recorded in the Q4 itself, and not in Q1? No, no. See, unless you make a sale, then only you can recognize a revenue, right? Yes. In our case, you have both finished goods and goods in transit. Certain finished goods are recognized as sale only when it reaches the customer destination. So the finished goods has two parts. One is what we physically have it at site, and the second one is in transit. Because certain Incoterms allows us to recognize revenue only when it reaches the customer. So when you take both of this, I would actually call it more as an aberration for this quarter. This is something I would actually say this is more an accounting, the way Sanjay put it across. When the inventory gets released, this overhead absorption happens. I think had we maintained a similar finished goods level like last quarter, you would not have seen this impact. Got it. So overhead from the last quarter is coming here because the inventory level- This is the P&L. Yeah. You are right. Exactly. Yeah. Okay. Thank you. Thank you. The next question is from the line of Saket from Sagari Capital. Please go ahead. Hey. Thanks for the opportunity. Am I audible? Yeah. Yeah. We talked about a lot of traction as far as CDMO RFPs are concerned. Could you share details around, say, how many projects we have currently, say, across different phases, say, in Q1, and what was the corresponding numbers, say, last year? Just to get a sense of how has the product pipeline in the CDMO, especially in the pharma PI/API space. How has that trended over the last year or so? I think we all understand that this CDMO part where we are participating with our customers during the clinical phase or regulatory phase or the commercial phase, it's a slow burn. Today, as we speak, and I mentioned in my narrative that we are sitting on about 20 RFPs. Six of them are in late stage, phase III or commercial. Last year, I think the number was 11 or 12. I do not remember exactly, but I think it was 11 or 12. You do see a consistent growth from last year to now and some products gaining traction, particularly in the chronic space. Now in addition to that chronic space, since we are looking at peptide fragments, that's a new opportunity that has opened up. Oh, fantastic. My next question would be, what is the typical asset turn for a pharma intermediate business? At a gross asset, is it 1.1.2? What's the asset turn? Overall at a company level, because our capacities are fungible, let's not go product category-wise or business segment-wise, but at a company level, I think we have clocked one of the best in the industry, north of four. Is it that net block or gross block, that four we are talking about? Four would be at net block, I guess. Net block, yes. At gross block, if CFO, sir, can respond. I'm just trying to understand, when you put in the new CapEx, what kind of numbers should we expect on a gross level? See, we have a pretty long-term plan in terms of our CapEx. We will shortly come back with a bigger outlook, which will take care of the future expansions. Our assessment over a period of, if you take the next five years, our asset turn should be somewhere close to 2.5 to 3. Okay. No, thanks for the opportunity and best wishes to the team. Thank you. As there are no further questions from the participants, I now hand the conference over to management for closing comments. Yeah. Thank you very much for your participation, and we will see you in the next investor call. Thank you very much. On behalf of Blue Jet Healthcare, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.